Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.36 |
| ▸ | TACR1 | P25103 | 3/20 | 0.36 |
| ▸ | ALB | P02768 | 1/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.34 |
| ▸ | DRD3 | P35462 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12156561 | 1.00 | SLC6A9 (0.44) | SLC6A9HSD17B10S1PR1TACR1ALB | |
| SCHEMBL12156548 | 1.00 | SLC6A9 (0.44) | SLC6A9HSD17B10S1PR1TACR1ALB | |
| SCHEMBL7593926 | 1.00 | SLC6A9 (0.44) | SLC6A9HSD17B10S1PR1TACR1ALB | |
| Hydrochloric Acid SCHEMBL29697028 | 0.98 | SLC6A9 (0.43) | SLC6A9HSD17B10S1PR1TACR1ALB | |
| SCHEMBL6625088 | 0.92 | SLC6A9 (0.39) | SLC6A9HSD17B10S1PR1TACR1ALB | |
| SCHEMBL24354419 | 0.91 | SLC6A9 (0.38) | SLC6A9HSD17B10S1PR1TACR1ALB | |
| SCHEMBL24354423 | 0.89 | ALDH1A1 (0.38) | SLC6A9HSD17B10S1PR1TACR1ALB | |
| SCHEMBL6628233 | 0.87 | SLC6A9 (0.36) | SLC6A9HSD17B10S1PR1TACR1ALB | |
| SCHEMBL3102765 | 0.86 | — | — | |
| SCHEMBL24274311 | 0.86 | SLC6A3 (0.42) | SLC6A9HSD17B10S1PR1ALBSLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018102890-A1 | VISUALIZATION CONSTRUCTS | THE UNIVERSITY OF QUEENSLAND (AU) | 2018-06-14 | — | — | WO | disclosed |
| US-8986650-B2 | Complex folate-NOTA-Ga68 | GUERBET (FR) | 2015-03-24 | — | — | US | disclosed |
| US-20120064003-A1 | COMPLEX FOLATE-NOTA-Ga68 | GUERBET (FR) | 2012-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120064003-A1 | COMPLEX FOLATE-NOTA-Ga68 | FOLR1, FOLR2, DHFR | SLC6A9 3203/4885HSD17B10 1388/4885S1PR1 1065/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.